Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407606 | 0.85 | ALDH1A1 (0.62) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL5397061 | 0.83 | CYP1A2 (0.60) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL5403168 | 0.83 | ALDH1A1 (0.58) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL5402743 | 0.76 | ALDH1A1 (0.51) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL9461198 | 0.73 | LMNA (0.43) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL1891091 | 0.72 | MAPT (0.63) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL9130552 | 0.72 | DHODH (0.55) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4395486 | 0.72 | ADORA3 (0.61) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL4081611 | 0.72 | MAPT (0.59) | MAPTGAAALDH1A1MEN1KMT2A | |
| SCHEMBL18997367 | 0.71 | MAPT (1.00) | MAPTGAAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241785-B2 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1394154-A1 | FIVE-MEMBERED HETEROCYCLIC ALKANOIC ACID DERIVATIVE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063775-A1 | Five-membered heterocyclic alkanoic acid derivative | SLC5A1, AHR, ALOX5 | MAPT 4614/4885GAA 1352/4885ALDH1A1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.